These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 24167025)

  • 1. Expression of p53 in imprint smears of endometrial carcinoma.
    Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P
    Diagn Cytopathol; 2014 May; 42(5):416-22. PubMed ID: 24167025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Ki-67 as proliferation biomarker in imprint smears of endometrial carcinoma.
    Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P
    Diagn Cytopathol; 2013 Mar; 41(3):212-7. PubMed ID: 21965052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of cyclooxygenase-2 in imprint smears of endometrial carcinoma.
    Kosmas K; Mitropoulou G; Stamoulas M; Marouga A
    Diagn Cytopathol; 2020 Nov; 48(11):1086-1092. PubMed ID: 32433831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of an immunocytochemical double-labeling staining can display the distribution of Bcl-2/Ki-67 cells in endometrial adenocarcinomas as well as in normal endometrium.
    Mourtzikou A; Kosmas K; Marouga A; Stamouli M; Pouliakis A; Karakitsos P
    Clin Lab; 2012; 58(1-2):133-44. PubMed ID: 22372356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of phosphatase and tensin homologue in imprint smears of endometrial carcinoma.
    Kosmas K; Mitropoulou G; Provatas I; Stamoulas M; Marouga A
    Cytopathology; 2018 Dec; 29(6):558-564. PubMed ID: 30007089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytodiagnosis of endometrial carcinoma and hyperplasia on imprint smears with additional immunocytochemistry using Ki-67 and p53 biomarkers.
    Apostolou G; Apostolou N; Nikolaidou C; Kavantzas N; Patsouris E; Athanassiadou P
    Cytopathology; 2014 Apr; 25(2):86-94. PubMed ID: 24118263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade.
    Urabe R; Hachisuga T; Kurita T; Kagami S; Kawagoe T; Matsuura Y; Shimajiri S
    J Obstet Gynaecol Res; 2014 Mar; 40(3):812-9. PubMed ID: 24246002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Ki-67, p53, Bcl-2, and Cox-2 biomarkers for low-grade endometrial cancer and disordered proliferative/benign hyperplastic endometrium by imprint cytology.
    Apostolou G; Apostolou N; Biteli M; Kavantzas N; Patsouris E; Athanassiadou P
    Diagn Cytopathol; 2014 Feb; 42(2):134-42. PubMed ID: 23729350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
    Fadare O; Parkash V
    Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Endometrial cancer, turned out to be an endometroid ovarian cancer stage II].
    Lazarov N; Lazarov L; Laarov S; Velev V; Ananiev J
    Akush Ginekol (Sofiia); 2011; 50(6):48-50. PubMed ID: 22452068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic utility of phosphatase and tensin homolog, beta-catenin, and p53 for endometrial carcinoma by thin-layer endometrial preparations.
    Norimatsu Y; Miyamoto M; Kobayashi TK; Moriya T; Shimizu K; Yanoh K; Tsukayama C; Miyake Y; Ohno E
    Cancer; 2008 Jun; 114(3):155-64. PubMed ID: 18431720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of histological types of endometrial cancer by endometrial cytology.
    Okadome M; Saito T; Nishiyama N; Ariyoshi K; Shimamoto K; Shimada T; Kodama K; Imamura S; Nishiyama K; Taguchi K
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1931-9. PubMed ID: 25056473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
    Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
    Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression.
    Watanabe J; Yokoyama Y; Futagami M; Mizunuma H; Yoshioka H; Washiya K; Hana K; Endou H; Okayasu I
    Int J Gynecol Cancer; 2014 May; 24(4):659-63. PubMed ID: 24694899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis?
    Gülseren V; Kocaer M; Özdemir İA; Çakır İ; Sancı M; Güngördük K
    Curr Probl Cancer; 2020 Feb; 44(1):100498. PubMed ID: 31395281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma.
    Obata T; Nakamura M; Mizumoto Y; Iizuka T; Ono M; Terakawa J; Daikoku T; Fujiwara H
    PLoS One; 2017; 12(11):e0188641. PubMed ID: 29190668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy.
    Bonfitto VL; de Angelo Andrade LA
    Sao Paulo Med J; 2003 Jul; 121(4):163-6. PubMed ID: 14595509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
    Brett MA; Atenafu EG; Singh N; Ghatage P; Clarke BA; Nelson GS; Bernardini MQ; Köbel M
    Int J Gynecol Pathol; 2021 Mar; 40(2):116-123. PubMed ID: 32265358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 overexpression as a prognostic indicator in endometrial carcinoma.
    Ozalp S; Yalcin OT; Tanir HM; Kabukcuoglu S; Erol G
    Eur J Gynaecol Oncol; 2003; 24(3-4):275-8. PubMed ID: 12807239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study.
    Athanassiadou P; Athanassiades P; Grapsa D; Gonidi M; Athanassiadou AM; Stamati PN; Patsouris E
    Int J Gynecol Cancer; 2007; 17(3):697-704. PubMed ID: 17504383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.